O	0	8	Hedgehog	Hedgehog	NN	B-NP
O	9	18	signaling	signaling	NN	I-NP
O	19	21	in	in	IN	B-PP
O	22	25	the	the	DT	B-NP
O	26	32	murine	murine	JJ	I-NP
B-Cancer	33	41	melanoma	melanoma	NN	I-NP
O	42	58	microenvironment	microenvironment	NN	I-NP
O	58	59	.	.	.	O

O	60	63	The	The	DT	B-NP
O	64	72	Hedgehog	Hedgehog	NNP	I-NP
B-Immaterial_anatomical_entity	73	86	intercellular	intercellular	JJ	I-NP
O	87	96	signaling	signaling	NN	I-NP
O	97	104	pathway	pathway	NN	I-NP
O	105	114	regulates	regulate	VBZ	B-VP
B-Cell	115	119	cell	cell	NN	B-NP
O	120	133	proliferation	proliferation	NN	I-NP
O	134	137	and	and	CC	O
O	138	153	differentiation	differentiation	NN	B-NP
O	153	154	.	.	.	O

O	155	159	This	This	DT	B-NP
O	160	167	pathway	pathway	NN	I-NP
O	168	171	has	have	VBZ	B-VP
O	172	176	been	be	VBN	I-VP
O	177	187	implicated	implicate	VBN	I-VP
O	188	190	to	to	TO	I-VP
O	191	195	play	play	VB	I-VP
O	196	197	a	a	DT	B-NP
O	198	202	role	role	NN	I-NP
O	203	205	in	in	IN	B-PP
O	206	209	the	the	DT	B-NP
O	210	222	pathogenesis	pathogenesis	NN	I-NP
O	223	225	of	of	IN	B-PP
B-Cancer	226	232	cancer	cancer	NN	B-NP
O	233	236	and	and	CC	B-PP
O	237	239	in	in	IN	B-PP
B-Multi-tissue_structure	240	249	embryonic	embryonic	JJ	B-NP
I-Multi-tissue_structure	250	255	blood	blood	NN	I-NP
I-Multi-tissue_structure	256	262	vessel	vessel	NN	I-NP
O	263	274	development	development	NN	I-NP
O	274	275	.	.	.	O

O	276	278	In	In	IN	B-PP
O	279	282	the	the	DT	B-NP
O	283	290	current	current	JJ	I-NP
O	291	296	study	study	NN	I-NP
O	296	297	,	,	,	O
O	298	306	Hedgehog	Hedgehog	NN	B-NP
O	307	316	signaling	signaling	NN	I-NP
O	317	319	in	in	IN	B-PP
B-Cancer	320	325	tumor	tumor	NN	B-NP
O	326	333	related	related	JJ	I-NP
B-Multi-tissue_structure	334	345	vasculature	vasculature	NN	I-NP
O	346	349	and	and	CC	I-NP
O	350	366	microenvironment	microenvironment	NN	I-NP
O	367	370	was	be	VBD	B-VP
O	371	379	examined	examine	VBN	I-VP
O	380	385	using	use	VBG	B-VP
B-Cell	386	391	human	human	JJ	B-NP
I-Cell	392	401	umbilical	umbilical	JJ	I-NP
I-Cell	402	406	vein	vein	NN	I-NP
I-Cell	407	418	endothelial	endothelial	JJ	I-NP
I-Cell	419	424	cells	cell	NNS	I-NP
O	425	428	and	and	CC	O
B-Cell	429	434	B16F0	B16F0	NN	B-NP
O	435	436	(	(	(	O
O	436	442	murine	murine	JJ	B-NP
B-Cancer	443	451	melanoma	melanoma	NN	I-NP
O	451	452	)	)	)	O
B-Cancer	453	459	tumors	tumor	NNS	B-NP
O	460	466	models	model	NNS	I-NP
O	466	467	.	.	.	O

O	468	471	Use	Use	NN	B-NP
O	472	474	of	of	IN	B-PP
O	475	484	exogenous	exogenous	JJ	B-NP
O	485	490	Sonic	Sonic	JJ	I-NP
O	491	499	hedgehog	hedgehog	NN	I-NP
O	500	501	(	(	(	O
O	501	504	Shh	Shh	NN	B-NP
O	504	505	)	)	)	O
O	506	513	peptide	peptide	NN	B-NP
O	514	527	significantly	significantly	RB	B-ADVP
O	528	537	increased	increase	VBD	B-VP
O	538	542	BrdU	BrdU	NN	B-NP
O	543	556	incorporation	incorporation	NN	I-NP
O	557	559	in	in	IN	B-PP
B-Cell	560	571	endothelial	endothelial	JJ	B-NP
I-Cell	572	577	cells	cell	NNS	I-NP
O	578	580	in	in	FW	B-PP
O	581	586	vitro	vitro	FW	B-NP
O	587	589	by	by	IN	B-PP
O	590	591	a	a	DT	B-NP
O	592	598	factor	factor	NN	I-NP
O	599	601	of	of	IN	B-PP
O	602	603	2	2	CD	B-NP
O	604	605	(	(	(	O
O	605	606	P	P	NN	B-NP
O	608	612	less	less	JJR	B-NP
O	613	617	than	than	IN	I-NP
O	619	620	0	0	CD	I-NP
O	620	621	.	.	.	I-NP
O	621	624	001	001	CD	I-NP
O	624	625	)	)	)	O
O	625	626	.	.	.	O

O	627	630	The	The	DT	B-NP
O	631	639	Hedgehog	Hedgehog	NNP	I-NP
O	640	647	pathway	pathway	NN	I-NP
O	648	658	antagonist	antagonist	NN	I-NP
O	659	670	cyclopamine	cyclopamine	NN	I-NP
O	671	682	effectively	effectively	RB	B-ADVP
O	683	690	reduced	reduce	VBD	B-VP
O	691	694	Shh	Shh	NN	B-NP
O	694	695	-	-	HYPH	B-NP
O	695	702	induced	induce	VBN	I-NP
O	703	716	proliferation	proliferation	NN	I-NP
O	717	719	to	to	TO	B-PP
O	720	727	control	control	NN	B-NP
O	728	734	levels	level	NNS	I-NP
O	734	735	.	.	.	O

O	736	738	To	To	TO	B-VP
O	739	744	study	study	VB	I-VP
O	745	753	Hedgehog	Hedgehog	NN	B-NP
O	754	763	signaling	signaling	NN	I-NP
O	764	766	in	in	FW	B-ADVP
O	767	771	vivo	vivo	FW	I-ADVP
O	772	773	a	a	DT	B-NP
B-Cancer	774	778	hind	hind	NN	I-NP
I-Cancer	779	783	limb	limb	NN	I-NP
I-Cancer	784	789	tumor	tumor	NN	I-NP
O	790	795	model	model	NN	I-NP
O	796	800	with	with	IN	B-PP
O	801	804	the	the	DT	B-NP
B-Cell	805	810	B16F0	B16F0	NN	I-NP
I-Cell	811	815	cell	cell	NN	I-NP
I-Cell	816	820	line	line	NN	I-NP
O	821	824	was	be	VBD	B-VP
O	825	829	used	use	VBN	I-VP
O	829	830	.	.	.	O

O	831	840	Treatment	Treatment	NN	B-NP
O	841	845	with	with	IN	B-PP
O	846	848	25	25	CD	B-NP
O	849	851	mg	mg	NN	I-NP
O	851	852	/	/	SYM	B-NP
O	852	854	kg	kg	NN	I-NP
O	855	866	cyclopamine	cyclopamine	NN	I-NP
O	867	880	significantly	significantly	RB	B-ADVP
O	881	891	attenuated	attenuate	VBD	B-VP
O	892	896	BrdU	BrdU	NN	B-NP
O	897	910	incorporation	incorporation	NN	I-NP
O	911	913	in	in	IN	B-PP
B-Cell	914	919	tumor	tumor	NN	B-NP
I-Cell	920	925	cells	cell	NNS	I-NP
O	926	935	threefold	threefold	RB	B-ADVP
O	936	937	(	(	(	O
O	937	938	P	P	NN	B-NP
O	940	944	less	less	JJR	B-NP
O	945	949	than	than	IN	I-NP
O	951	952	0	0	CD	I-NP
O	952	953	.	.	.	I-NP
O	953	956	001	001	CD	I-NP
O	956	957	)	)	)	O
O	957	958	,	,	,	O
O	959	961	in	in	IN	B-PP
B-Cancer	962	967	tumor	tumor	NN	B-NP
O	968	975	related	related	JJ	I-NP
B-Cell	976	987	endothelial	endothelial	JJ	I-NP
I-Cell	988	993	cells	cell	NNS	I-NP
O	994	1003	threefold	threefold	RB	B-ADVP
O	1004	1005	(	(	(	O
O	1005	1006	P	P	NN	B-NP
O	1007	1008	=	=	SYM	B-VP
O	1009	1010	0	0	CD	B-NP
O	1010	1011	.	.	SYM	I-NP
O	1011	1014	004	004	CD	I-NP
O	1014	1015	)	)	)	O
O	1015	1016	,	,	,	O
O	1017	1020	and	and	CC	O
O	1021	1028	delayed	delay	VBN	B-NP
B-Cancer	1029	1034	tumor	tumor	NN	I-NP
O	1035	1041	growth	growth	NN	I-NP
O	1042	1044	by	by	IN	B-PP
O	1045	1046	4	4	CD	B-NP
O	1047	1051	days	day	NNS	I-NP
O	1051	1052	.	.	.	O

O	1053	1073	Immunohistochemistry	Immunohistochemistry	NN	B-NP
O	1074	1082	revealed	reveal	VBD	B-VP
O	1083	1087	that	that	IN	B-SBAR
O	1088	1091	the	the	DT	B-NP
O	1092	1100	Hedgehog	Hedgehog	NN	I-NP
O	1101	1109	receptor	receptor	NN	I-NP
O	1110	1117	Patched	Patched	NNP	B-NP
O	1118	1121	was	be	VBD	B-VP
O	1122	1131	localized	localized	JJ	B-ADJP
O	1132	1134	to	to	TO	B-PP
O	1135	1138	the	the	DT	B-NP
B-Tissue	1139	1144	tumor	tumor	NN	I-NP
I-Tissue	1145	1151	stroma	stroma	NN	I-NP
O	1152	1155	and	and	CC	O
O	1156	1160	that	that	IN	B-SBAR
B-Cell	1161	1166	B16F0	B16F0	NN	B-NP
I-Cell	1167	1172	cells	cell	NNS	I-NP
O	1173	1182	expressed	express	VBD	B-VP
O	1183	1186	Shh	Shh	NN	B-NP
O	1187	1194	peptide	peptide	NN	I-NP
O	1194	1195	.	.	.	O

O	1196	1207	Furthermore	Furthermore	RB	B-ADVP
O	1207	1208	,	,	,	O
O	1209	1214	mouse	mouse	NN	B-NP
B-Cell	1215	1224	embryonic	embryonic	JJ	I-NP
I-Cell	1225	1236	fibroblasts	fibroblast	NNS	I-NP
O	1237	1245	required	require	VBD	B-VP
O	1246	1249	the	the	DT	B-NP
O	1250	1258	presence	presence	NN	I-NP
O	1259	1261	of	of	IN	B-PP
B-Cell	1262	1267	B16F0	B16F0	NN	B-NP
I-Cell	1268	1273	cells	cell	NNS	I-NP
O	1274	1276	to	to	TO	B-VP
O	1277	1284	express	express	VB	I-VP
O	1285	1292	Patched	Patch	VBN	I-VP
O	1293	1295	in	in	IN	B-PP
O	1296	1297	a	a	DT	B-NP
O	1298	1300	co	co	AFX	I-NP
O	1300	1301	-	-	HYPH	I-NP
O	1301	1308	culture	culture	NN	I-NP
O	1309	1314	assay	assay	NN	I-NP
O	1315	1321	system	system	NN	I-NP
O	1321	1322	.	.	.	O

O	1323	1328	These	These	DT	B-NP
O	1329	1336	studies	study	NNS	I-NP
O	1337	1345	indicate	indicate	VBP	B-VP
O	1346	1350	that	that	IN	B-SBAR
O	1351	1354	Shh	Shh	NN	B-NP
O	1355	1362	peptide	peptide	NN	I-NP
O	1363	1371	produced	produce	VBN	B-VP
O	1372	1374	by	by	IN	B-PP
B-Cell	1375	1383	melanoma	melanoma	NN	B-NP
I-Cell	1384	1389	cells	cell	NNS	I-NP
O	1390	1397	induces	induce	VBZ	B-VP
O	1398	1405	Patched	Patch	VBN	I-VP
O	1406	1416	expression	expression	NN	B-NP
O	1417	1419	in	in	IN	B-PP
B-Cell	1420	1431	fibroblasts	fibroblast	NNS	B-NP
O	1431	1432	.	.	.	O

O	1433	1435	To	To	TO	B-VP
O	1436	1441	study	study	VB	I-VP
B-Cancer	1442	1447	tumor	tumor	NN	B-NP
O	1448	1455	related	related	JJ	I-NP
O	1456	1468	angiogenesis	angiogenesis	NN	I-NP
O	1469	1470	a	a	DT	B-NP
B-Multi-tissue_structure	1471	1479	vascular	vascular	JJ	I-NP
O	1480	1486	window	window	NN	I-NP
O	1487	1492	model	model	NN	I-NP
O	1493	1496	was	be	VBD	B-VP
O	1497	1501	used	use	VBN	I-VP
O	1502	1504	to	to	TO	B-VP
O	1505	1512	monitor	monitor	VB	I-VP
B-Cancer	1513	1518	tumor	tumor	NN	B-NP
O	1519	1530	vascularity	vascularity	NN	I-NP
O	1530	1531	.	.	.	O

O	1532	1541	Treatment	Treatment	NN	B-NP
O	1542	1546	with	with	IN	B-PP
O	1547	1558	cyclopamine	cyclopamine	NN	B-NP
O	1559	1572	significantly	significantly	RB	B-ADVP
O	1573	1583	attenuated	attenuate	VBD	B-VP
B-Multi-tissue_structure	1584	1592	vascular	vascular	JJ	B-NP
O	1593	1602	formation	formation	NN	I-NP
O	1603	1605	by	by	IN	B-PP
O	1606	1607	a	a	DT	B-NP
O	1608	1614	factor	factor	NN	I-NP
O	1615	1617	of	of	IN	B-PP
O	1618	1619	2	2	CD	B-NP
O	1619	1620	.	.	.	O
O	1620	1621	5	5	CD	B-NP
O	1622	1623	(	(	(	O
O	1623	1624	P	P	NN	B-NP
O	1626	1630	less	less	JJR	B-NP
O	1631	1635	than	than	IN	I-NP
O	1637	1638	0	0	CD	I-NP
O	1638	1639	.	.	.	I-NP
O	1639	1642	001	001	CD	I-NP
O	1642	1643	)	)	)	O
O	1644	1647	and	and	CC	O
O	1648	1655	altered	alter	VBN	B-VP
B-Multi-tissue_structure	1656	1664	vascular	vascular	JJ	B-NP
O	1665	1675	morphology	morphology	NN	I-NP
O	1675	1676	.	.	.	O

O	1677	1688	Furthermore	Furthermore	RB	B-ADVP
O	1688	1689	,	,	,	O
O	1690	1701	cyclopamine	cyclopamine	NN	B-NP
O	1702	1709	reduced	reduce	VBD	B-VP
B-Multi-tissue_structure	1710	1715	tumor	tumor	NN	B-NP
I-Multi-tissue_structure	1716	1721	blood	blood	NN	I-NP
I-Multi-tissue_structure	1722	1728	vessel	vessel	NN	I-NP
O	1729	1741	permeability	permeability	NN	I-NP
O	1742	1744	to	to	TO	B-PP
O	1745	1749	FITC	FITC	NN	B-NP
O	1750	1757	labeled	labeled	JJ	I-NP
O	1758	1765	dextran	dextran	NN	I-NP
O	1766	1771	while	while	IN	B-SBAR
O	1772	1778	having	have	VBG	B-VP
O	1779	1781	no	no	DT	B-NP
O	1782	1788	effect	effect	NN	I-NP
O	1789	1791	on	on	IN	B-PP
O	1792	1798	normal	normal	JJ	B-NP
B-Multi-tissue_structure	1799	1804	blood	blood	NN	I-NP
I-Multi-tissue_structure	1805	1812	vessels	vessel	NNS	I-NP
O	1812	1813	.	.	.	O

O	1814	1819	These	These	DT	B-NP
O	1820	1827	studies	study	NNS	I-NP
O	1828	1835	suggest	suggest	VBP	B-VP
O	1836	1840	that	that	IN	B-SBAR
O	1841	1849	Hedgehog	Hedgehog	NN	B-NP
O	1850	1859	signaling	signaling	NN	I-NP
O	1860	1869	regulates	regulate	VBZ	B-VP
B-Cancer	1870	1878	melanoma	melanoma	NN	B-NP
O	1879	1886	related	related	JJ	I-NP
B-Multi-tissue_structure	1887	1895	vascular	vascular	JJ	I-NP
O	1896	1905	formation	formation	NN	I-NP
O	1906	1909	and	and	CC	I-NP
O	1910	1918	function	function	NN	I-NP
O	1918	1919	.	.	.	O

